Summary of Dermira, Inc. (NASDAQ:DERM) Ratings on May 17, 2018

May 17, 2018 - By Mary Anderson

Dermira, Inc. (NASDAQ:DERM) Corporate Logo
Big Money Sentiment decreased to 1.27 in Q4 2017. It has change of 0.76, from 2017Q3’s 2.03. The ratio dived due to Dermira, Inc. positioning: 16 sold and 35 reduced. 25 funds amassed positions and 40 increased positions. Investors holded 41.09 million in 2017Q3 but now own 38.81 million shares or 5.56% less.
Parallax Volatility Advisers Limited Partnership accumulated 25,947 shs or 0% of the stock. New York State Common Retirement Fund reported 0% of its capital in Dermira, Inc. (NASDAQ:DERM). Marshall Wace Llp accumulated 0.02% or 16,091 shs. 10,000 are owned by Ardsley Advisory. Services Automobile Association accumulated 22,268 shs. Renaissance Limited holds 0% or 100,600 shs in its capital. Eventide Asset Limited Liability Co owns 0.18% invested in Dermira, Inc. (NASDAQ:DERM) for 124,000 shs. Parametric Portfolio Assoc Limited Liability Com holds 36,683 shs. The Minnesota-based Ameriprise has invested 0% in Dermira, Inc. (NASDAQ:DERM). Landscape Capital Management Ltd Liability Com stated it has 0.04% of its capital in Dermira, Inc. (NASDAQ:DERM). Moreover, Paloma Prtnrs has 0.01% invested in Dermira, Inc. (NASDAQ:DERM) for 21,329 shs. D E Shaw invested in 0% or 94,348 shs. Atlantic Gp Limited Liability Company holds 0% in Dermira, Inc. (NASDAQ:DERM) or 500 shs. Bnp Paribas Arbitrage invested in 0% or 8,073 shs. Citigroup holds 529 shs or 0% of its capital.

Dermira, Inc. registered $1.01 million net activity with 0 buys and 10 insider sales since December 13, 2017. WIGGANS THOMAS G sold $137,566 worth of Dermira, Inc. (NASDAQ:DERM) or 5,000 shs on Wednesday, December 13. Shares for $16,818 were sold by Cohen David E on Tuesday, January 2. $499,354 worth of Dermira, Inc. (NASDAQ:DERM) was sold by Griffith Christopher M..

Dermira, Inc. (NASDAQ:DERM) Ratings Coverage

Total analysts of 5 have positions in Dermira (NASDAQ:DERM) as follows: 3 rated it a “Buy”, 0 with “Sell” and 2 with “Hold”. The positive are 60%. Since December 5, 2017 according to StockzIntelligence Inc Dermira has 9 analyst reports. On Tuesday, December 12 the firm has “Buy” rating by Mizuho given. On Thursday, February 22 the stock has “Buy” rating by Cantor Fitzgerald. On Wednesday, January 17 the stock of Dermira, Inc. (NASDAQ:DERM) earned “Buy” rating by Leerink Swann. On Thursday, May 3 the rating was maintained by Cantor Fitzgerald with “Buy”. The company rating was initiated by Guggenheim on Tuesday, December 5. On Tuesday, March 6 the firm has “Neutral” rating by Guggenheim given. On Monday, March 5 the rating was downgraded by Mizuho to “Hold”. On Friday, February 23 the rating was maintained by Mizuho with “Buy”. Listed here are Dermira, Inc. (NASDAQ:DERM) PTs and latest ratings.

03/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $20.0000 Maintain
06/03/2018 Broker: Guggenheim Old Rating: Buy New Rating: Neutral Downgrade
05/03/2018 Broker: Mizuho Rating: Hold Downgrade
05/03/2018 Broker: Cowen & Co Rating: Buy New Target: $25.0
23/02/2018 Broker: Mizuho Rating: Buy New Target: $39.0 Maintain
22/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $45.0 Maintain
17/01/2018 Broker: Leerink Swann Rating: Buy New Target: $48.0 Maintain
12/12/2017 Broker: Mizuho Rating: Buy New Target: $39.0 Maintain
05/12/2017 Broker: Guggenheim Rating: Buy Initiate

DERM is reaching $11.13 during the last trading session, after increased 3.53%.Currently Dermira, Inc. is downtrending after 77.97% change in last May 17, 2017. DERM has 165,295 shares volume. DERM underperformed by 89.52% the S&P 500.

Dermira, Inc., a biopharmaceutical company, engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the United States.The firm is worth $465.77 million. The companyÂ’s late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne.Last it reported negative earnings. It has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia.

For more Dermira, Inc. (NASDAQ:DERM) news released briefly go to: Globenewswire.com, Nasdaq.com, Nasdaq.com, Globenewswire.com or Globenewswire.com. The titles are as follows: “Christopher Horan Joins Dermira as Chief Technical Operations Officer” released on April 19, 2018, “Dermira and Cameran Eubanks Team Up to Raise Awareness of Excessive Sweating for the 15 Million People Living …” on May 02, 2018, “Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)” with a publish date: May 08, 2018, “Dermira to Present at Deutsche Bank 43rd Annual Healthcare Conference” and the last “Dermira to Host Analyst & Investor Day on May 24, 2018” with publication date: May 14, 2018.

Dermira, Inc. (NASDAQ:DERM) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.